For research use only. Not for therapeutic Use.
JK-P3 is novel inhibitor of VEGFR-2. JK-P3 is a pyrazole-based inhibitor of VEGFR-2 (IC50 = 7.8 μM). JK-P3 inhibits FGFR 1/3 kinase activity in vitro, but has no effect on FGFR signaling in cell-based assays. The compound blocks wound healing and tube formation in HUVEC without effecting endothelial cell proliferation.
Catalog Number | I014419 |
CAS Number | 942655-44-9 |
Synonyms | JK-P3, 3,4-Dimethoxy-N-(5-phenyl-1H-pyrazol-3-yl)-benzamide;3,4-Dimethoxy-N-(5-phenyl-1H-pyrazol-3-yl)-benzamide |
Molecular Formula | C18H17N3O3 |
Purity | ≥95% |
Target | VEGFR |
Solubility | Soluble in DMSO |
InChI | InChI=1S/C18H17N3O3/c1-23-15-9-8-13(10-16(15)24-2)18(22)19-17-11-14(20-21-17)12-6-4-3-5-7-12/h3-11H,1-2H3,(H2,19,20,21,22) |
InChIKey | QAZJUVDICQNITG-UHFFFAOYSA-N |
SMILES | O=C(NC1=NNC(C2=CC=CC=C2)=C1)C3=CC=C(OC)C(OC)=C3 |
Reference | </br>1: Kankanala J, Latham AM, Johnson AP, Homer-Vanniasinkam S, Fishwick CW, Ponnambalam S. A combinatorial in silico and cellular approach to identify a new class of compounds that target VEGFR2 receptor tyrosine kinase activity and angiogenesis. Br J Pharmacol. 2012 May;166(2):737-48. doi: 10.1111/j.1476-5381.2011.01801.x. PubMed PMID: 22141913; PubMed Central PMCID: PMC3417501.</br> |